MediGene Receives One-Time Payment for License Agreement with Glaxo Group
20-Dec-2005
The payment from Glaxo, combined with Eligard® sales, will ensure that Medigene will reach previous established guidance for 2005 of revenues of 20 million EUR. MediGene management is now postponing the finalization of the Polyphenon® E marketing partnership in order to review new proposals received after the recent FDA acceptance of the New Drug Application for Polyphenon® E-Ointment for the Treatment of Genital Warts.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.